Trending...
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement - 132
- Battery Coin Ignites $5B Token Presale to Power Bitcoin Ethical AI and Hemp Battery
- Mbariket Launches U.S. Client Services to Deliver Trusted Business Solutions in Nigeria
Expansion accommodates significant growth in demand for its new rapid point-of-care HIV tests intended to break the chain of new HIV infections worldwide
BEAVERTON, Ore. - nvtip -- Sedia Biosciences Corporation, formerly of Portland Oregon, today announced the relocation to and opening of their new assay development and manufacturing facility in Beaverton, Oregon. The 27,000 square foot facility provides for both current growth as well as additional near-term expansion and enables immediate scale-up of manufacturing capacity as well as research capabilities. Equipped with multiple state of the art, environmentally controlled production, quality and research laboratories, high throughput production equipment, and expanded warehouse capacity, the facility is also designed to accommodate the "new normal" of business in a pandemic challenged environment. The new facility will have a much needed immediate impact on production capacity of Sedia's products, now being used in partnership with the U.S. Centers for Disease Control and Prevention (CDC, www.cdc.gov), PEPFAR (President's Emergency Plan for AIDS Relief, www.pepfar.gov), and other NGOs and stakeholders working with Sedia.
More on nvtip.com
Dr. Ronald Mink, Chief Science Officer and President, who co-founded Sedia with Roger Gale, Sedia's CEO and Chairman, stated that "Sedia has been focused on fulfilling the growing demand from CDC, PEPFAR and others for our AsantéTM HIV Rapid Recency® Assay. This test is the first rapid point-of-care assay with the capability to both quickly verify HIV status of a patient, and determine if they are a recent, or 'new' infection. Public Health agencies worldwide use this valuable information to identify where new outbreaks of HIV are occurring. Tracking these early cases is important as they have the highest likelihood of transmitting HIV and may be doing so unknowingly. Such individuals can be the source of new and sudden outbreaks of the disease. Our products are intended to break this cycle. COVID has shown that what the world needs is simple, fast and accurate diagnostic tests in large numbers. This is what we do. Sedia is dynamic, growing rapidly and is very relevant to the current global health crisis."
According to Nancy Lime, Vice President Operations, "Globally, an estimated 19% of persons living with HIV are unaware of their status. Individuals with recent HIV infections can be responsible for up to 40% of new infections in their community. Since HIV can remain asymptomatic and undetected for months, recently infected individuals can continue to pass the virus to others. New approaches and tools are needed to fight HIV and other global pandemics and this technology can potentially be applied to other diseases, including the SARS-CoV-2 'COVID-19' virus and sexually transmitted diseases."
More on nvtip.com
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our commitment is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and business people that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
More on nvtip.com
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Pacsun Joins UFC International Fight Week with Exclusive Collection and First-Ever UFC X Activation
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Christina Aldan Announces Website Update Highlighting Massage Therapy Training
Dr. Ronald Mink, Chief Science Officer and President, who co-founded Sedia with Roger Gale, Sedia's CEO and Chairman, stated that "Sedia has been focused on fulfilling the growing demand from CDC, PEPFAR and others for our AsantéTM HIV Rapid Recency® Assay. This test is the first rapid point-of-care assay with the capability to both quickly verify HIV status of a patient, and determine if they are a recent, or 'new' infection. Public Health agencies worldwide use this valuable information to identify where new outbreaks of HIV are occurring. Tracking these early cases is important as they have the highest likelihood of transmitting HIV and may be doing so unknowingly. Such individuals can be the source of new and sudden outbreaks of the disease. Our products are intended to break this cycle. COVID has shown that what the world needs is simple, fast and accurate diagnostic tests in large numbers. This is what we do. Sedia is dynamic, growing rapidly and is very relevant to the current global health crisis."
According to Nancy Lime, Vice President Operations, "Globally, an estimated 19% of persons living with HIV are unaware of their status. Individuals with recent HIV infections can be responsible for up to 40% of new infections in their community. Since HIV can remain asymptomatic and undetected for months, recently infected individuals can continue to pass the virus to others. New approaches and tools are needed to fight HIV and other global pandemics and this technology can potentially be applied to other diseases, including the SARS-CoV-2 'COVID-19' virus and sexually transmitted diseases."
More on nvtip.com
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- Intelligent Technical Solutions Appoints Dave Dyas as Senior Vice President of Channels & Alliances
- Wingderm USA Takes the Lead at TAS 2025, Cementing Its Local Presence in the U.S. USA - English USA - English USA - Français USA - Deutsch USA - español
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our commitment is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and business people that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
Source: Sedia Biosciences Corporation
0 Comments
Latest on nvtip.com
- Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI)
- Byrd Davis Alden & Henrichson Launches Independence Day Safe Ride Initiative with 500 Free Uber Credits
- $10,000 Buy-In WSOP Main Event Giveaway + More with Jamie Gold and MyStandard
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Battery Coin Ignites $5B Token Presale to Power Bitcoin Ethical AI and Hemp Battery
- Generative Engine Optimization (GEO) by Emanuel Rose Earns Top 25 Ranking on Amazon
- Laugh More, Spend Less: Delirious Comedy Club Launches Hot Summer Savings!
- Mbariket Launches U.S. Client Services to Deliver Trusted Business Solutions in Nigeria
- Las Vegas Sands Donates $515,000 to The WASH Foundation for Water and Hygiene Initiatives
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
- Rebels Wireless Inc. Launches iPhone Buying Service in Las Vegas dba "Sell iPhone
- Suzanne Harp named Managing Director in Texas, USA
- $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine